What’s new in molecular genetic pathology 2021: solid tumors and NGS panel selection
Guoli Chen, Patricia C. Tsang
Journal of Pathology and Translational Medicine · 2021
doi:10.4132/jptm.2021.09.01 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
The linchpin of precision medicine is molecular genetic and genomic testing. Molecular biomarkers are important for establishing precise diagnoses and for predicting therapeutic responses that enable cancer patients to receive personalized and targeted treatment. Below are highlights of the current considerations in next generation sequencing (NGS) panel selection, and in molecular testing of solid tumors of the lung, digestive system, thyroid and soft tissue.
Abstract licence: CC BY-NC
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.